Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

Launched by DANA-FARBER CANCER INSTITUTE · Aug 4, 2021

Keywords

ClinConnect Summary

This clinical trial is exploring whether a 16-week exercise program can help women with ovarian or endometrial cancer who are undergoing chemotherapy. The program includes both aerobic exercises (like walking or cycling) and resistance training (like lifting weights), all supervised virtually. The goal is to see if this exercise can improve leg strength, reduce numbness or tingling in the hands and feet caused by chemotherapy, and impact certain markers in the blood related to inflammation.

To participate in this trial, women aged 18 and older who have recently been diagnosed with stage III or IV ovarian or endometrial cancer and are starting their first round of chemotherapy may be eligible. It's important that their doctor approves their participation in moderate to vigorous exercise. Participants will engage in the exercise program and will also need to provide some blood samples for the study. This trial is currently recruiting, so if you or someone you know fits these criteria, it could be an opportunity to contribute to important research while potentially improving quality of life during treatment.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Newly diagnosed patients with stages III-IV ovarian or endometrial cancer
• • Receiving first-line carboplatin and paclitaxel chemotherapy after surgery
• • ≥18 years, children under the age of 18 will be excluded due to rarity of disease
• • Physician's clearance to participate in moderate-vigorous intensity exercise
• • Able to read, write, and understand English
• • Ability to understand and the willingness to sign an informed consent document
• • Willing to undergo two venous blood draws for the study
• Exclusion Criteria:
• • Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist
• • Participants with uncontrolled intercurrent illness, as determined by the treating oncologist
• • Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist
• • Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)